Loading...
A leading theory on the pathogenesis of Alzheimer disease (AD) is that overproduction of amyloid, particularly amyloid-β, is involved. Tarenflurbil, a drug that influences the production of amyloid-β through the formation of shorter, less-toxic chains, showed promise in a small clinical trial. In this larger, randomized, industry-sponsored trial, 1684 patients (mean age, 75) with mild AD received tarenflurbil or placebo. Most were taking acetylcholinesterase inhibitors, memantine (Namenda), or both.
At 18-month follow-up, the two groups did not differ in absolute levels or rates of cognitive decline nor in several secondary outcomes. The dropout rate was significantly higher in the intervention group than in the control group. Significantly …